List of Excipients in Branded Drug ZYLOPRIM

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Prometheus Laboratories Inc	ZYLOPRIM	allopurinol	65483-991	LACTOSE
Prometheus Laboratories Inc	ZYLOPRIM	allopurinol	65483-991	MAGNESIUM STEARATE
Prometheus Laboratories Inc	ZYLOPRIM	allopurinol	65483-991	POVIDONE
Prometheus Laboratories Inc	ZYLOPRIM	allopurinol	65483-991	STARCH, POTATO
Casper Pharma LLC	ZYLOPRIM	allopurinol	70199-015	LACTOSE

Zyloprim Excipient Strategy and Commercial Opportunities

Last updated: October 26, 2026

Zyloprim is the branded allopurinol immediate-release tablet used to reduce uric acid production in gout, hyperuricemia associated with cancer therapy, and related conditions. Its core product has limited patent protection and faces extensive generic competition. Commercial opportunity therefore depends on formulation differentiation rather than protection of allopurinol itself.

The strongest opportunities are lactose-free tablets, lower-dose and pediatric presentations, oral liquids or dispersible products, and formulations designed to improve dissolution or administration in patients with dysphagia and renal impairment. Any new product must preserve allopurinol bioequivalence, manage hypersensitivity risk, and avoid excipient changes that create tolerability or labeling barriers.

What is Zyloprim and how is it regulated?

Zyloprim contains allopurinol, a xanthine oxidase inhibitor. The U.S. reference product is associated with NDA 016084 and was approved in the 1960s. Current U.S. dosage forms are immediate-release tablets, principally 100 mg and 300 mg strengths. The product is not a biologic and has no biosimilar pathway.

Attribute	Zyloprim
Active ingredient	Allopurinol
Therapeutic class	Xanthine oxidase inhibitor
Primary indications	Gout, hyperuricemia, tumor lysis-related hyperuricemia
U.S. dosage form	Immediate-release tablet
Principal strengths	100 mg and 300 mg
FDA pathway	Original NDA; generic products approved through ANDAs
Reference NDA	016084
Biosimilar exposure	None
Main competitive threat	Low-cost allopurinol generics

The approved labeling identifies lactose, magnesium stearate, and starch among the inactive ingredients for the tablet formulation, although excipient descriptions can vary by market, strength, manufacturer, and product revision.[1] A commercial development program should confirm the current reference-label composition against the applicable FDA package insert and DailyMed record before selecting a target composition.

What excipients are used in Zyloprim tablets?

The reference formulation uses a conventional solid oral excipient platform:

Excipient function	Likely reference-product role	Commercial implication
Lactose	Diluent and tablet bulk agent	Creates a lactose-free differentiation opportunity
Starch	Filler, binder, or disintegrant depending on process	Supports conventional immediate release
Magnesium stearate	Lubricant	Excess use can slow wetting and dissolution
Allopurinol	Active pharmaceutical ingredient	Poor aqueous solubility requires process control

Allopurinol has limited aqueous solubility. Particle size, polymorphic form, wetting, granulation conditions, lubricant concentration, compression force, and disintegration performance can affect dissolution. Excipient selection should therefore be linked to a defined dissolution target rather than treated as a simple cost-reduction exercise.

The reference excipient system is commercially practical but offers limited differentiation. A generic manufacturer can generally pursue a conventional lactose-starch tablet if it achieves pharmaceutical equivalence and bioequivalence. A differentiated product requires a specific patient or manufacturing benefit.

What excipient strategies can improve allopurinol tablets?

Lactose-free formulation

A lactose-free Zyloprim alternative is the most straightforward excipient-led opportunity. Lactose can be replaced with:

• Microcrystalline cellulose
• Mannitol
• Dibasic calcium phosphate
• Pregelatinized starch
• Coprocessed cellulose-based fillers

Microcrystalline cellulose can improve compactability and tablet robustness. Mannitol can provide a cleaner mouthfeel in chewable or orally disintegrating products, but its hygroscopicity and cost require control. Dibasic calcium phosphate may improve tablet hardness but can complicate dissolution and is less suitable for every formulation process.

The commercial case is strongest where institutional buyers, pharmacies, or patients actively avoid lactose. The opportunity is likely incremental rather than a basis for premium pricing by itself.

Improved dissolution formulation

A dissolution-focused formulation may use:

• Reduced particle-size allopurinol
• Wetting agents at low concentrations
• Crospovidone, croscarmellose sodium, or sodium starch glycolate
• Spray-dried or granulated API-excipient systems
• Hydrophilic polymer-based dispersion approaches

Surfactants such as sodium lauryl sulfate can improve wetting but may increase gastrointestinal tolerability concerns and should be used conservatively. Superdisintegrants can reduce disintegration time, although they do not automatically solve low API solubility.

A formulation should be screened against the reference product across pH conditions and agitation rates. The target is consistent release rather than a rapid in vitro profile that creates an in vivo mismatch.

Modified-release formulation

A modified-release allopurinol product could reduce dosing frequency or smooth exposure, but it carries a higher development burden. Allopurinol is converted to oxypurinol, which has a longer half-life and contributes to pharmacologic activity. A modified-release product would therefore need to characterize both allopurinol and oxypurinol exposure.

Potential barriers include:

• Establishing a clinically meaningful dosing advantage
• Demonstrating comparable urate control
• Managing renal impairment and oxypurinol accumulation
• Supporting a 505(b)(2) or new-drug development strategy
• Generating clinical evidence beyond standard bioequivalence

Modified release is a potential patentable platform but is less attractive than a simple differentiated immediate-release product unless a commercial partner has strong clinical-development capabilities.

Orally disintegrating or dispersible tablets

An orally disintegrating tablet could address patients with dysphagia, older adults, and patients receiving treatment during acute gout management. Candidate excipients include mannitol, crospovidone, low-substituted hydroxypropyl cellulose, and taste-masking polymers.

Allopurinol has a characteristic taste profile that may limit an ODT product. Taste masking could use polymer coating, ion-exchange resins, lipid barriers, or microencapsulation. These technologies can improve patient acceptability but may slow dissolution or increase tablet mass.

An ODT would have to establish a clear administration advantage over the existing 100 mg and 300 mg tablets. A dispersible tablet may be more practical than a true ODT if the product is intended for administration in water.

What commercial opportunities exist for Zyloprim-compatible excipient products?

Which patient segments are most attractive?

The most defensible targets are patients who experience a specific administration or formulation problem:

Target segment	Product concept	Commercial rationale
Lactose-sensitive patients	Lactose-free 100 mg and 300 mg tablets	Simple differentiation
Dysphagia patients	ODT or dispersible tablet	Administration convenience
Pediatric patients	Oral solution or low-dose dispersible form	Dose flexibility
Elderly patients	Smaller, easier-to-swallow tablets	Adherence support
Renal-impaired patients	50 mg or scored low-dose tablet	More precise titration
Hospital patients	Unit-dose, dispersible, or liquid product	Medication-administration efficiency
Oncology patients	Ready-to-use liquid or pediatric-compatible product	Tumor lysis protocols and inpatient use

A 50 mg strength may have the clearest clinical utility for dose titration, particularly where renal function requires conservative initiation. Its commercial value depends on payer reimbursement, pharmacy substitution rules, and whether existing tablets can be safely split.

Oral liquid opportunity

An allopurinol oral solution could address pediatric use, dysphagia, feeding-tube administration, and hospital pharmacy needs. The major technical issues are:

• API solubility
• Chemical and microbial stability
• Sedimentation if formulated as a suspension
• Dose uniformity
• Palatability
• Compatibility with enteral tubing
• Preservative tolerability

A suspension may be more realistic than a true solution because of allopurinol’s solubility limitations. A ready-to-use product would have greater convenience, while a powder-for-reconstitution product could improve shelf stability and reduce shipping weight.

An oral liquid may qualify for regulatory differentiation through a 505(b)(2) application or may require a different pathway depending on the reference product and the proposed labeling. The regulatory strategy must be established before investing in formulation patents.

What patents protect Zyloprim and allopurinol products?

The original Zyloprim and allopurinol composition-of-matter protection expired many years ago. The current U.S. opportunity is not based on exclusivity for allopurinol itself.

Public FDA records for the legacy Zyloprim tablet do not indicate a commercially meaningful, current Orange Book patent barrier comparable to the patent estates of newer branded drugs.[2][3] No active branded-drug patent strategy should be assumed for conventional allopurinol tablets.

A new formulation could generate protection around:

• Specific excipient ratios
• Particle-size distributions
• Dissolution profiles
• Taste-masked particles
• Oral liquid stability systems
• Modified-release coatings
• Administration through feeding tubes
• Low-dose or pediatric formulations
• Manufacturing processes that control polymorph or particle attributes

Formulation patents must claim a technically reproducible feature. Broad claims covering ordinary use of lactose substitutes, starch, cellulose, or standard disintegrants are vulnerable to invalidity and design-around arguments.

When does Zyloprim lose exclusivity?

Zyloprim has already lost market exclusivity in the conventional sense. Generic allopurinol tablets are widely available, and an ANDA applicant generally does not face the branded product’s historical patent barrier.

Exclusivity category	Current position
Active ingredient patent	Expired
Original product exclusivity	Expired
FDA orphan exclusivity	Not applicable to standard Zyloprim tablets
Pediatric exclusivity	No current commercial significance
Orange Book patent stay	No generally material current barrier identified
Generic substitution	Established
Biosimilar exclusivity	Not applicable

Are there Paragraph IV challenges to Zyloprim?

Paragraph IV litigation is unlikely to be commercially significant for standard Zyloprim tablets because the relevant composition patents expired decades ago and the product is already subject to broad generic competition. A future Paragraph IV dispute would be more likely to involve a newly patented formulation, delivery system, or method of use than conventional allopurinol tablets.

A new patent owner could face an ANDA challenge against:

• A controlled-release formulation
• A liquid formulation
• A taste-masked product
• A combination product
• A new low-dose or pediatric presentation

A listed patent could create a 30-month stay under the Hatch-Waxman framework if the statutory requirements are met. That protection would attach to the new formulation, not to legacy Zyloprim tablets.

What method-of-use patents could support a new product?

Allopurinol has established uses, so broad method-of-use claims are difficult to defend. More focused claims may address:

• Dose selection based on renal function
• Prevention of tumor lysis syndrome in defined patient groups
• Administration with a particular formulation for feeding-tube patients
• Use in patients unable to tolerate a specified excipient
• Pharmacokinetic control through modified release

Method-of-use patents require careful claim drafting and infringement analysis. A generic manufacturer may use a skinny-label strategy for a patented indication if the remaining unpatented indications support approval and marketing.

What manufacturing and intellectual-property barriers matter?

The main barriers are technical rather than patent-based.

API and solid-state control

Allopurinol’s dissolution performance can be affected by particle size, crystallinity, milling, and blending. A manufacturer that changes API source or milling conditions may need to repeat dissolution and stability work.

Content uniformity

Low-dose products, especially 50 mg tablets, can create blend uniformity challenges. Ordered mixing, granulation, or premix strategies may be needed to control content uniformity.

Stability

Moisture, lubricant distribution, compression force, and packaging can affect tablet hardness, disintegration, and dissolution. Blister packaging may provide a stronger moisture barrier than high-density polyethylene bottles but can increase unit cost.

Manufacturing scale-up

Wet granulation may provide robust content uniformity and tablet strength but adds equipment, processing time, and drying controls. Direct compression can reduce cost but may be less forgiving of API flow and compressibility variability.

How strong is the patent estate for an excipient-differentiated allopurinol product?

The patent estate for conventional Zyloprim is weak because the basic product is long genericized. A new formulation can have moderate protection if it combines:

1. A clinically meaningful administration advantage.
2. A defined composition or process.
3. Reproducible performance data.
4. A formulation that is difficult to design around.
5. Regulatory exclusivity or a meaningful market-access advantage.

The strongest candidates are taste-masked pediatric products, stable oral liquids, feeding-tube-compatible formulations, and modified-release systems supported by clinical data. A lactose-free immediate-release tablet alone is more likely to produce a marketing distinction than durable patent value.

What litigation, settlement, and licensing issues affect the opportunity?

No material legacy settlement structure is required to enter the conventional allopurinol tablet market. Generic manufacturers generally do not need a license from the Zyloprim sponsor to market an unpatented allopurinol tablet.

Licensing becomes relevant when a company controls:

• A protected modified-release platform
• A liquid or suspension technology
• A taste-masking system
• A specialized manufacturing process
• A branded product with regulatory exclusivity
• A device or administration system

A licensing deal should allocate responsibility for bioequivalence, formulation patents, manufacturing validation, pharmacovigilance, and supply continuity. The commercial value of a license depends on whether it protects a real market segment or merely adds a formulation label to a commodity tablet.

How does Zyloprim compare with competing urate-lowering drugs?

Product	Active ingredient	Formulation opportunity	Patent position
Zyloprim	Allopurinol	Lactose-free, liquid, ODT, low-dose	Legacy product; genericized
Generic allopurinol	Allopurinol	Cost-focused immediate-release tablets	Highly competitive
Uloric/F من?	Febuxostat	Alternative xanthine oxidase inhibition	Separate safety and patent history
Probenecid	Probenecid	Renal-function and adherence considerations	Genericized
Lesinurad products	Lesinurad	Combination and transporter inhibition	Commercial and regulatory history differs
Pegloticase	Pegloticase	Biologic infusion product	Biologic, not directly substitutable

Febuxostat provides the closest pharmacologic comparison, but its safety labeling, pricing, and prescriber preferences differ. Allopurinol’s main competitive advantage is low cost and extensive clinical familiarity. A new excipient platform must improve use or adherence without undermining that cost advantage.

What generic launch risks exist?

A new Zyloprim-related product faces five principal risks:

• The target market may substitute generic tablets immediately.
• Payers may refuse a premium for excipient differentiation.
• A liquid or ODT may require clinical evidence that exceeds its commercial return.
• Excipient changes may alter dissolution or tolerability.
• Patent claims may be narrow and easy to design around.

The lowest-risk launch is a lactose-free immediate-release tablet using well-characterized excipients. The highest-upside concept is a pediatric and dysphagia-focused product with a stable, palatable liquid or dispersible dosage form. Modified release has the greatest patent potential but also the highest development and regulatory risk.

What is the commercial outlook for Zyloprim excipient innovation?

The conventional allopurinol tablet market is mature and price-sensitive. Revenue exposure for the branded Zyloprim product is constrained by generic substitution, while a differentiated product could capture value in narrower segments.

Commercial ranking:

1. Lactose-free 100 mg and 300 mg tablets: low development risk, limited premium.
2. 50 mg tablet: moderate opportunity, useful for renal-dose titration.
3. Dispersible tablet: moderate opportunity, differentiated administration.
4. Oral suspension or solution: higher opportunity in pediatric and institutional markets.
5. ODT with taste masking: potentially attractive, but formulation risk is high.
6. Modified release: highest patent potential, highest clinical and regulatory burden.

Key Takeaways

• Zyloprim is an old allopurinol product with no meaningful current composition-of-matter exclusivity.
• Conventional allopurinol tablets are highly genericized and price-sensitive.
• The reference excipient system includes lactose, starch, and magnesium stearate.
• Lactose-free tablets offer the simplest commercial differentiation.
• Liquid, dispersible, ODT, and 50 mg products address clearer patient-use problems.
• Formulation patents are possible but must claim measurable technical performance.
• Paragraph IV and Orange Book litigation are not central risks for standard tablets.
• Modified-release products offer stronger patent potential but require substantial pharmacokinetic and clinical work.
• The most credible commercial opportunity is an administration-focused product for dysphagia, pediatric use, renal-dose titration, or institutional dispensing.

FAQs about Zyloprim excipient and formulation opportunities

Can lactose be removed from Zyloprim without changing bioequivalence?

Yes, lactose can generally be replaced with microcrystalline cellulose, mannitol, starch, or another suitable diluent. The replacement must preserve dissolution, content uniformity, stability, and bioequivalence.

Is a 50 mg allopurinol tablet commercially valuable?

A 50 mg strength can support lower starting doses and renal-function-based titration. Its value depends on pharmacy demand, payer coverage, and whether tablet splitting already satisfies the target use.

Does allopurinol have biosimilar risk?

No. Allopurinol is a small-molecule active ingredient. Competitive products are regulated as generic drugs, not biosimilars.

Can an allopurinol oral liquid receive new patent protection?

Yes, if the product has a novel and non-obvious composition, stability system, taste-masking approach, or administration method. Ordinary syrup or suspension excipients alone are unlikely to provide strong protection.

What is the best excipient opportunity for a generic Zyloprim manufacturer?

A lactose-free, low-dose, or dispersible immediate-release product offers the best balance of development cost, regulatory complexity, and commercial differentiation. A liquid or modified-release product offers more upside but carries greater development risk.

References

1. U.S. Food and Drug Administration. (n.d.). Zyloprim (allopurinol) tablets: U.S. prescribing information. FDA/DailyMed.

2. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Zyloprim, NDA 016084. https://www.accessdata.fda.gov/scripts/cder/daf/

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (2015). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. FDA Guidance for Industry.

5. U.S. Food and Drug Administration. (2019). ANDAs for certain highly purified synthetic peptide drug products that refer to listed drugs of recombinant origin. FDA Guidance for Industry.